{"entity":{"type":"insider","cik":"0001612528","url":"/insider/0001612528","json_url":"/insider/0001612528.json","name":"COATS LONNEL","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":53,"n_filings":12,"first":"2017-09-18","last":"2024-11-22","span_basis":"filed_date"},"name_variants":[{"name":"COATS LONNEL","source":"filing","n_filings":12,"first_seen":"2017-09-18","last_seen":"2024-11-22"}],"transactions":[{"id":2900858,"accession":"0001415889-24-027545","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-027545","line_url":"/filing/0001415889-24-027545#line-6","is_derivative":false,"issuer_cik":"0001597264","issuer_name":"Blueprint Medicines Corp","issuer_ticker":"BPMC","issuer_name_source":null,"issuer_url":"/issuer/0001597264","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9824.0,"shares_display":"9,824","price_per_share":94.87,"price_display":"94.87","price_state":"stated","total_value":932002.88,"total_display":"932,002.88","total_whole":"932,003","shares_owned_after":2242.0,"shares_owned_after_display":"2,242","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-21","filed_date":"2024-11-22","scope":"insider"},{"id":2900854,"accession":"0001415889-24-027545","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-027545","line_url":"/filing/0001415889-24-027545","is_derivative":false,"issuer_cik":"0001597264","issuer_name":"Blueprint Medicines Corp","issuer_ticker":"BPMC","issuer_name_source":null,"issuer_url":"/issuer/0001597264","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":93.765475,"price_display":"93.77","price_state":"stated","total_value":937654.75,"total_display":"937,654.75","total_whole":"937,655","shares_owned_after":12279.0,"shares_owned_after_display":"12,279","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-20","filed_date":"2024-11-22","scope":"insider","n_lines":3},{"id":7971496,"accession":"0001127602-23-027850","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-027850","line_url":"/filing/0001127602-23-027850#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90000.0,"shares_display":"90,000","price_per_share":1.0533,"price_display":"1.05","price_state":"stated","total_value":94797.0,"total_display":"94,797.00","total_whole":"94,797","shares_owned_after":914359.0,"shares_owned_after_display":"914,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider"},{"id":8213756,"accession":"0001127602-23-027279","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-027279","line_url":"/filing/0001127602-23-027279#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":1.01,"price_display":"1.01","price_state":"stated","total_value":10100.0,"total_display":"10,100.00","total_whole":"10,100","shares_owned_after":824359.0,"shares_owned_after_display":"824,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-10","filed_date":"2023-11-13","scope":"insider"},{"id":7866750,"accession":"0001127602-23-019560","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-019560","line_url":"/filing/0001127602-23-019560#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.16,"price_display":"2.16","price_state":"stated","total_value":21600.0,"total_display":"21,600.00","total_whole":"21,600","shares_owned_after":814359.0,"shares_owned_after_display":"814,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-29","filed_date":"2023-06-29","scope":"insider"},{"id":8730371,"accession":"0001127602-23-019405","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-23-019405","line_url":"/filing/0001127602-23-019405#line-2","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.1792,"price_display":"2.18","price_state":"stated","total_value":21792.0,"total_display":"21,792.00","total_whole":"21,792","shares_owned_after":804359.0,"shares_owned_after_display":"804,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-26","filed_date":"2023-06-26","scope":"insider"},{"id":8730368,"accession":"0001127602-23-019405","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-019405","line_url":"/filing/0001127602-23-019405#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.495,"price_display":"2.50","price_state":"stated","total_value":24950.0,"total_display":"24,950.00","total_whole":"24,950","shares_owned_after":794359.0,"shares_owned_after_display":"794,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-23","filed_date":"2023-06-26","scope":"insider"},{"id":8699393,"accession":"0001127602-23-019231","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-019231","line_url":"/filing/0001127602-23-019231#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":2.31,"price_display":"2.31","price_state":"stated","total_value":92400.0,"total_display":"92,400.00","total_whole":"92,400","shares_owned_after":784359.0,"shares_owned_after_display":"784,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-22","filed_date":"2023-06-22","scope":"insider"},{"id":8640968,"accession":"0001127602-19-028814","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-19-028814","line_url":"/filing/0001127602-19-028814#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":3.1,"price_display":"3.10","price_state":"stated","total_value":155000.0,"total_display":"155,000.00","total_whole":"155,000","shares_owned_after":227539.0,"shares_owned_after_display":"227,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-18","filed_date":"2019-09-19","scope":"insider"},{"id":7823209,"accession":"0001127602-19-028744","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001127602-19-028744","line_url":"/filing/0001127602-19-028744","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":3.128061184,"price_display":"3.13","price_state":"stated","total_value":156403.0592,"total_display":"156,403.06","total_whole":"156,403","shares_owned_after":177539.0,"shares_owned_after_display":"177,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-17","filed_date":"2019-09-18","scope":"insider","n_lines":5},{"id":7904375,"accession":"0001127602-19-027072","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001127602-19-027072","line_url":"/filing/0001127602-19-027072#line-8","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":1.398,"price_display":"1.40","price_state":"stated","total_value":4194.0,"total_display":"4,194.00","total_whole":"4,194","shares_owned_after":127539.0,"shares_owned_after_display":"127,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-08-19","filed_date":"2019-08-20","scope":"insider"},{"id":7904372,"accession":"0001127602-19-027072","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001127602-19-027072","line_url":"/filing/0001127602-19-027072","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37000.0,"shares_display":"37,000","price_per_share":1.3468843243243243,"price_display":"1.35","price_state":"stated","total_value":49834.72,"total_display":"49,834.72","total_whole":"49,835","shares_owned_after":124539.0,"shares_owned_after_display":"124,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-08-16","filed_date":"2019-08-20","scope":"insider","n_lines":7},{"id":8289081,"accession":"0001179110-19-009616","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001179110-19-009616","line_url":"/filing/0001179110-19-009616","is_derivative":false,"issuer_cik":"0001597264","issuer_name":"Blueprint Medicines Corp","issuer_ticker":"BPMC","issuer_name_source":null,"issuer_url":"/issuer/0001597264","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":82.400718,"price_display":"82.40","price_state":"stated","total_value":824007.18,"total_display":"824,007.18","total_whole":"824,007","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-08-15","filed_date":"2019-08-19","scope":"insider","n_lines":3},{"id":5139229,"accession":"0001127602-17-032220","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-17-032220","line_url":"/filing/0001127602-17-032220#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":9.91,"price_display":"9.91","price_state":"stated","total_value":99100.0,"total_display":"99,100.00","total_whole":"99,100","shares_owned_after":42985.0,"shares_owned_after_display":"42,985","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-15","filed_date":"2017-11-15","scope":"insider"},{"id":4816722,"accession":"0001127602-17-027540","txn_seq":25,"anchor":"line-25","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-25","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5200.0,"shares_display":"5,200","price_per_share":12.54,"price_display":"12.54","price_state":"stated","total_value":65208.0,"total_display":"65,208.00","total_whole":"65,208","shares_owned_after":12085.0,"shares_owned_after_display":"12,085","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816718,"accession":"0001127602-17-027540","txn_seq":24,"anchor":"line-24","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-24","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4253.0,"shares_display":"4,253","price_per_share":12.53,"price_display":"12.53","price_state":"stated","total_value":53290.09,"total_display":"53,290.09","total_whole":"53,290","shares_owned_after":19585.0,"shares_owned_after_display":"19,585","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816715,"accession":"0001127602-17-027540","txn_seq":23,"anchor":"line-23","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-23","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3300.0,"shares_display":"3,300","price_per_share":12.52,"price_display":"12.52","price_state":"stated","total_value":41316.0,"total_display":"41,316.00","total_whole":"41,316","shares_owned_after":6885.0,"shares_owned_after_display":"6,885","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816712,"accession":"0001127602-17-027540","txn_seq":22,"anchor":"line-22","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-22","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3247.0,"shares_display":"3,247","price_per_share":12.5366,"price_display":"12.54","price_state":"stated","total_value":40706.3402,"total_display":"40,706.34","total_whole":"40,706","shares_owned_after":15332.0,"shares_owned_after_display":"15,332","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816710,"accession":"0001127602-17-027540","txn_seq":21,"anchor":"line-21","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-21","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2400.0,"shares_display":"2,400","price_per_share":12.55,"price_display":"12.55","price_state":"stated","total_value":30120.0,"total_display":"30,120.00","total_whole":"30,120","shares_owned_after":22385.0,"shares_owned_after_display":"22,385","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816706,"accession":"0001127602-17-027540","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-20","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":12.57,"price_display":"12.57","price_state":"stated","total_value":25140.0,"total_display":"25,140.00","total_whole":"25,140","shares_owned_after":26336.0,"shares_owned_after_display":"26,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816702,"accession":"0001127602-17-027540","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-19","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1951.0,"shares_display":"1,951","price_per_share":12.56,"price_display":"12.56","price_state":"stated","total_value":24504.56,"total_display":"24,504.56","total_whole":"24,505","shares_owned_after":24336.0,"shares_owned_after_display":"24,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816698,"accession":"0001127602-17-027540","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-18","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1200.0,"shares_display":"1,200","price_per_share":12.5766,"price_display":"12.58","price_state":"stated","total_value":15091.92,"total_display":"15,091.92","total_whole":"15,092","shares_owned_after":28436.0,"shares_owned_after_display":"28,436","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816695,"accession":"0001127602-17-027540","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-17","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1200.0,"shares_display":"1,200","price_per_share":12.519,"price_display":"12.52","price_state":"stated","total_value":15022.8,"total_display":"15,022.80","total_whole":"15,023","shares_owned_after":30479.0,"shares_owned_after_display":"30,479","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816691,"accession":"0001127602-17-027540","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-16","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":600.0,"shares_display":"600","price_per_share":12.6166,"price_display":"12.62","price_state":"stated","total_value":7569.96,"total_display":"7,569.96","total_whole":"7,570","shares_owned_after":31985.0,"shares_owned_after_display":"31,985","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816687,"accession":"0001127602-17-027540","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-15","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":600.0,"shares_display":"600","price_per_share":12.5166,"price_display":"12.52","price_state":"stated","total_value":7509.96,"total_display":"7,509.96","total_whole":"7,510","shares_owned_after":26936.0,"shares_owned_after_display":"26,936","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816685,"accession":"0001127602-17-027540","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-14","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400.0,"shares_display":"400","price_per_share":12.6361,"price_display":"12.64","price_state":"stated","total_value":5054.44,"total_display":"5,054.44","total_whole":"5,054","shares_owned_after":32985.0,"shares_owned_after_display":"32,985","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816680,"accession":"0001127602-17-027540","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-13","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400.0,"shares_display":"400","price_per_share":12.535,"price_display":"12.54","price_state":"stated","total_value":5014.0,"total_display":"5,014.00","total_whole":"5,014","shares_owned_after":19985.0,"shares_owned_after_display":"19,985","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816674,"accession":"0001127602-17-027540","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-12","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400.0,"shares_display":"400","price_per_share":12.5162,"price_display":"12.52","price_state":"stated","total_value":5006.48,"total_display":"5,006.48","total_whole":"5,006","shares_owned_after":29179.0,"shares_owned_after_display":"29,179","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816671,"accession":"0001127602-17-027540","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-11","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":306.0,"shares_display":"306","price_per_share":12.537,"price_display":"12.54","price_state":"stated","total_value":3836.322,"total_display":"3,836.32","total_whole":"3,836","shares_owned_after":30785.0,"shares_owned_after_display":"30,785","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816668,"accession":"0001127602-17-027540","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-10","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.6466,"price_display":"12.65","price_state":"stated","total_value":3793.98,"total_display":"3,793.98","total_whole":"3,794","shares_owned_after":31385.0,"shares_owned_after_display":"31,385","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816665,"accession":"0001127602-17-027540","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-9","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.6232,"price_display":"12.62","price_state":"stated","total_value":3786.96,"total_display":"3,786.96","total_whole":"3,787","shares_owned_after":32585.0,"shares_owned_after_display":"32,585","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816663,"accession":"0001127602-17-027540","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-8","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.6161,"price_display":"12.62","price_state":"stated","total_value":3784.83,"total_display":"3,784.83","total_whole":"3,785","shares_owned_after":32285.0,"shares_owned_after_display":"32,285","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816659,"accession":"0001127602-17-027540","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-7","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.5761,"price_display":"12.58","price_state":"stated","total_value":3772.83,"total_display":"3,772.83","total_whole":"3,773","shares_owned_after":31085.0,"shares_owned_after_display":"31,085","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816655,"accession":"0001127602-17-027540","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-6","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.5498,"price_display":"12.55","price_state":"stated","total_value":3764.94,"total_display":"3,764.94","total_whole":"3,765","shares_owned_after":27236.0,"shares_owned_after_display":"27,236","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816651,"accession":"0001127602-17-027540","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-5","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.4866,"price_display":"12.49","price_state":"stated","total_value":3745.98,"total_display":"3,745.98","total_whole":"3,746","shares_owned_after":3285.0,"shares_owned_after_display":"3,285","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"},{"id":4816647,"accession":"0001127602-17-027540","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001127602-17-027540","line_url":"/filing/0001127602-17-027540#line-4","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":"0001612528","owner_name":"COATS LONNEL","owner_display_name":"COATS LONNEL","owner_url":"/insider/0001612528","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.485,"price_display":"12.48","price_state":"stated","total_value":3745.5,"total_display":"3,745.50","total_whole":"3,746","shares_owned_after":3585.0,"shares_owned_after_display":"3,585","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-18","scope":"insider"}],"collapsed":true,"next_cursor":"2017-09-15|4816647","ledger_fault":false,"count":{"value":53,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":46,"open_market":true},{"code":"S","label":"Open-market sale","n":7,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":53},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001597264","name":"Blueprint Medicines Corp","url":"/issuer/0001597264","role":"Director","n_filings":2,"first_seen":"2019-08-19","last_seen":"2024-11-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001062822","name":"LEXICON PHARMACEUTICALS, INC.","url":"/issuer/0001062822","role":"Director, Officer (Chief Executive Officer)","n_filings":10,"first_seen":"2017-09-18","last_seen":"2023-11-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001612528","retrieved_at":"2026-08-26T18:06:04+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}